Faricimab(TD-HT073016) is a research-grade recombinant antibody targetingVascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Protein A/G purified from cell culture supernatant.
Accession
P15692 & O15123
Form
Liquid
Storage buffer
20 mM His, 140mM NaCl, pH6.0Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
Bispecific, RG7716, RO6867461, 1607793-29-2
Background
Zifibancimig is an anti-VEGFA/ANGPT2 IgG1κ monoclonal antibody.
Caption
SDS-PAGE for Research Grade Faricimab | Detects Human ANGPT2 in indirect ELISAs. ### Detects VEGFA in indirect ELISAs. ### Detects Recombinant Human VEGFA/VEGF165 Protein, C-His (Cat No.:HB941011) in indirect ELISA.
Note
For research use only. Not suitable for clinical or therapeutic use.